146 related articles for article (PubMed ID: 27580239)
1. Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent "Pimonidazole" in Hypoxia.
Masaki Y; Shimizu Y; Yoshioka T; Feng F; Zhao S; Higashino K; Numata Y; Kuge Y
PLoS One; 2016; 11(8):e0161639. PubMed ID: 27580239
[TBL] [Abstract][Full Text] [Related]
2. [Accumulation Mechanism of 2-Nitroimidazole-based Hypoxia Imaging Probes Revealed by Imaging Mass Spectrometry].
Shimizu Y
Yakugaku Zasshi; 2018; 138(11):1345-1352. PubMed ID: 30381642
[TBL] [Abstract][Full Text] [Related]
3. A Novel PET Probe "[
Shimizu Y; Zhao S; Yasui H; Nishijima KI; Matsumoto H; Shiga T; Tamaki N; Ogawa M; Kuge Y
Mol Imaging Biol; 2019 Feb; 21(1):122-129. PubMed ID: 29845425
[TBL] [Abstract][Full Text] [Related]
4. FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state.
Masaki Y; Shimizu Y; Yoshioka T; Nishijima KI; Zhao S; Higashino K; Numata Y; Tamaki N; Kuge Y
Ann Nucl Med; 2017 Oct; 31(8):596-604. PubMed ID: 28695498
[TBL] [Abstract][Full Text] [Related]
5. The accumulation mechanism of the hypoxia imaging probe "FMISO" by imaging mass spectrometry: possible involvement of low-molecular metabolites.
Masaki Y; Shimizu Y; Yoshioka T; Tanaka Y; Nishijima K; Zhao S; Higashino K; Sakamoto S; Numata Y; Yamaguchi Y; Tamaki N; Kuge Y
Sci Rep; 2015 Nov; 5():16802. PubMed ID: 26582591
[TBL] [Abstract][Full Text] [Related]
6. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of tumor hypoxia using 18F-labeled pimonidazole.
Busk M; Jakobsen S; Horsman MR; Mortensen LS; Iversen AB; Overgaard J; Nordsmark M; Ji X; Lee DY; Raleigh JR
Acta Oncol; 2013 Oct; 52(7):1300-7. PubMed ID: 23962243
[TBL] [Abstract][Full Text] [Related]
8. Mass Spectrometry Imaging of the Hypoxia Marker Pimonidazole in a Breast Tumor Model.
Mascini NE; Cheng M; Jiang L; Rizwan A; Podmore H; Bhandari DR; Römpp A; Glunde K; Heeren RM
Anal Chem; 2016 Mar; 88(6):3107-14. PubMed ID: 26891127
[TBL] [Abstract][Full Text] [Related]
9. Detection of different hypoxic cell subpopulations in human melanoma xenografts by pimonidazole immunohistochemistry.
Gulliksrud K; Vestvik IK; Galappathi K; Mathiesen B; Rofstad EK
Radiat Res; 2008 Nov; 170(5):638-50. PubMed ID: 18959463
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic cell turnover in different solid tumor lines.
Ljungkvist AS; Bussink J; Kaanders JH; Rijken PF; Begg AC; Raleigh JA; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1157-68. PubMed ID: 15913908
[TBL] [Abstract][Full Text] [Related]
11. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
12. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix.
Jankovic B; Aquino-Parsons C; Raleigh JA; Stanbridge EJ; Durand RE; Banath JP; MacPhail SH; Olive PL
Cytometry B Clin Cytom; 2006 Mar; 70(2):45-55. PubMed ID: 16456867
[TBL] [Abstract][Full Text] [Related]
13. Pimonidazole-alkyne conjugate for sensitive detection of hypoxia by Cu-catalyzed click reaction.
Tamura I; Sakamoto DM; Yi B; Saito Y; Yamada N; Takakusagi Y; Sando S
Anal Sci; 2024 Jun; 40(6):1061-1070. PubMed ID: 38478357
[TBL] [Abstract][Full Text] [Related]
14. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma.
Varia MA; Calkins-Adams DP; Rinker LH; Kennedy AS; Novotny DB; Fowler WC; Raleigh JA
Gynecol Oncol; 1998 Nov; 71(2):270-7. PubMed ID: 9826471
[TBL] [Abstract][Full Text] [Related]
15. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
Kaanders JH; Wijffels KI; Marres HA; Ljungkvist AS; Pop LA; van den Hoogen FJ; de Wilde PC; Bussink J; Raleigh JA; van der Kogel AJ
Cancer Res; 2002 Dec; 62(23):7066-74. PubMed ID: 12460928
[TBL] [Abstract][Full Text] [Related]
16. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
[TBL] [Abstract][Full Text] [Related]
17. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors.
Melo T; Duncan J; Ballinger JR; Rauth AM
J Nucl Med; 2000 Jan; 41(1):169-76. PubMed ID: 10647620
[TBL] [Abstract][Full Text] [Related]
18. Orally administered pimonidazole to label hypoxic tumor cells.
Bennewith KL; Raleigh JA; Durand RE
Cancer Res; 2002 Dec; 62(23):6827-30. PubMed ID: 12460894
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of [(18)F]F-GAZ, a novel oxygen-mimetic azomycin-glucose conjugate, for imaging hypoxic tumor.
Wuest M; Kumar P; Wang M; Yang J; Jans HS; Wiebe LI
Cancer Biother Radiopharm; 2012 Oct; 27(8):473-80. PubMed ID: 22746267
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
